Status:
COMPLETED
Effect of the HIV Protease Inhibitors Atazanavir and Lopinavir/Ritonavir on Cardiovascular Disease Risk Factors
Lead Sponsor:
Indiana University
Collaborating Sponsors:
National Heart, Lung, and Blood Institute (NHLBI)
Conditions:
Endothelial Dysfunction
Eligibility:
MALE
18-65 years
Phase:
NA
Brief Summary
HIV protease inhibitors (PIs) are a class of antiretroviral drugs used to inhibit viral replication. They do so by interfering with a key step in the replication process. Some HIV PIs have been associ...
Detailed Description
Antiretroviral therapy for HIV, particularly with the use of PIs, is associated with an increased risk of heart attack. Specific cardiovascular side effects seen with the use of some PIs include insul...
Eligibility Criteria
Inclusion
- Healthy and lean with normal lipids
- Not infected with HIV or viral hepatitis
Exclusion
Key Trial Info
Start Date :
November 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2006
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00720590
Start Date
November 1 2003
End Date
October 1 2006
Last Update
October 25 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Indiana University School of Medicine
Indianapolis, Indiana, United States, 46202